Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis | Synapse

January 1, 2017Open Access

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis

Key Points

Key points are not available for this paper at this time.

Abstract

In this issue, Nishio et al report the results of the multicentre phase II trial with nivolumab checkpoint inhibitor (CPI) immunotherapy in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC), who progressed after platinum-containing chemotherapy.1

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Johan Vansteenkiste (Sun,) studied this question.

synapsesocial.com/papers/6a16842a4021539c0f6569fd https://doi.org/https://doi.org/10.1136/esmoopen-2016-000119

Mark Helpful

Bookmark

Relay

View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015 · 8,550 citations
2Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer2002 · 1,373 citations
3Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC2016 · 71 citations
4Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib2004 · 181 citations
5Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S00032005 · 126 citations